Other languages Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Delayed Japan Exchange Other stock markets 21:38:56 2024-04-29 EDT			5-day change	1st Jan Change
434 ^JPY	+5.85%		+6.11%	-6.87%

04-22	Lull in Geopolitical Tensions Lifts Asian Stock Markets	MT
04-17	Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Poxel : reporte la publication de ses résultats annuels 2023	04-29
Lull in Geopolitical Tensions Lifts Asian Stock Markets	04-22
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	04-02
Roivant's anti-inflammatory drug succeeds in mid-stage study	04-02
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	03-15
US Inflation Report Lifts Asian Stock Markets	03-01
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	02-16
Japan's Nikkei slips after Fed chair signals delay in rate cut	01-31
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	01-31
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	01-31
Fed, China Property Outlooks Roil Asian Stock Markets	01-30
Japan's Nikkei rounds off 2023 with biggest yearly gain in a decade	12-29
Interest Rates, China Housing Measures Lift Asian Stock Markets	12-15
China Real Estate, FX Roil Asian Stock Markets	11-29
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®	11-02
Japanese Shares End Higher on Tuesday After BOJ Kept Rate Unchanged; Shares of Nippon Electric Glass Jump Over 10%	23-10-31
Sumitomo Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023	23-10-31
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-10-31
Flat China Price Report Dulls Asian Stock Markets	23-10-13
Poxel : les pertes se creusent, le titre décroche	23-09-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Other languages

Filters